轻度抗凝血酶缺乏与复发性静脉血栓栓塞风险:MEGA随访研究结果
基于人群的队列研究纳入2357例首次静脉血栓栓塞患者,按抗凝血酶活性百分位和功能水平分层,中位随访7.4年。最低抗凝血酶活性组(<第5百分位,<87%)较>第10百分位(>92%)复发风险调整HR为1.5(95%CI 1.0-2.3);<70% vs >80%的调整HR为3.7(95%CI 1.4-9.9)。研究证实轻度抗凝血酶缺乏是复发性静脉血栓栓塞的危险因素。
要点
- 轻度抗凝血酶缺乏(活性<正常第5百分位)与复发性静脉血栓栓塞风险增加相关。
- 抗凝血酶活性<70% vs >80%的患者复发VTE调整HR为3.7(95%CI 1.4-9.9)。
- 该关联在至少8年随访中持续存在,且不受血栓形成危险因素影响。
核心结论
- 本研究证实轻度抗凝血酶缺乏是复发性静脉血栓栓塞的危险因素。
研究设计与样本
- 基于人群的队列研究,纳入2357例首次静脉血栓栓塞患者,按抗凝血酶活性百分位(<第5百分位[<87%]、5-10th[87-92%]、>第10百分位[>92%])和功能抗凝血酶水平(<70%、70-80%、>80%)分层。
主要发现
- 中位随访7.4年,共发生361例复发事件(发生率2.5/100患者年)。
- 最低抗凝血酶活性组(<第5百分位,<87%)较>第10百分位(>92%)组复发VTE调整HR为1.5(95%CI 1.0-2.3)。
- 抗凝血酶<70%组 vs >80%组的静脉复发调整HR为3.7(95%CI 1.4-9.9)。
- 轻度抗凝血酶缺乏可预测至少8年随访期间的复发性VTE,且按血栓形成危险因素存在与否分层后关联仍存在。
- 排除采血时使用抗凝治疗及每日饮酒≥5杯的患者后,限制性分析未实质影响上述结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Mild antithrombin deficiency may increase the risk of recurrent venous thromboembolism (VTE). In a cohort study, we stratified patients with VTE to various cut-off antithrombin levels. A 1.6-3.7-fold increased risk of recurrent VTE was observed in the lowest antithrombin categories. Mild antithrombin deficiency (activity < 5th percentile of normal) increases recurrent VTE risk. SUMMARY: Background Mild antithrombin deficiency (previously defined as antithrombin activity below 70% or 80%) has been associated with a 2.4-3.5-fold increased risk of recurrent venous thromboembolism (VTE). This finding may have implications for duration of antithrombotic therapy in VTE patients with mild antithrombin deficiency. Objectives To externally validate whether mild antithrombin deficiency is a risk factor for recurrent VTE. Methods In a population-based cohort study, patients with a first VTE (n = 2357) were stratified according to percentile cut-off antithrombin levels (< 5th [< 87%], 5-10th [87-92%], > 10th percentile [> 92%]) and functional antithrombin levels (< 70%, 70-80%, > 80%). Results During a median follow-up of 7.4 years, 361 recurrent events occurred (incidence rate, 2.5/100 patient-years). We observed an increased risk of recurrent VTE in the lowest antithrombin activity category (< 5th percentile; < 87%) as compared with antithrombin activity that was > 10th percentile (> 92%), with an adjusted hazard ratio (HR) of 1.5 (95%CI, 1.0-2.3). When analyses were stratified to antithrombin cut-off criteria of< 70% vs. patients with antithrombin activity > 80%, the adjusted HR for venous recurrence was 3.7 (95% CI, 1.4-9.9). Mild antithrombin deficiency was able to predict recurrent VTE over at least 8 years of follow-up and the association remained present when the population was stratified to the presence or absence of thrombosis risk factors. Restriction analyses, where patients who used anticoagulation at time of blood draw and those who reported drinking ≥ 5 glasses alcohol daily were excluded, did not materially affect these outcomes. Conclusion This study confirms that mild antithrombin deficiency is a risk factor for recurrent VTE.
引用
- Sokol J, Timp JF, le Cessie S, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. J Thromb Haemost. 2018. PMID: 29377625. doi:10.1111/jth.13960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。